Zuyan Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zuyan Fan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Biqi Dai
Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University
1 shared publicationBohou Li
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
1 shared publicationCaiwei Tan
Institute of Pharmacology and Toxicology, Zhejiang University College of Pharmaceutical Sciences
1 shared publicationChunjie Lin
Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University
1 shared publication- Deli Huang
Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University
1 shared publication - Dong Fang
Life Sciences Institute, Zhejiang University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in advanced prostate cancer. Here we identify follistatin (FST), TGFβ superfamily antagonist, as a key driver of AR-independence and treatment resistance. During anti-AR therapy, cancer cells progressively lose the positive feedback loop between AR and BMP signaling, leading to FST upregulation that further suppresses this circuit. FST antagonizes BMP11-dependent AR maintenance and upregulates the lineage plasticity regulator SOX9, conferring resistance to enzalutamide while promoting stem-like properties and metastatic capabilities. FST also remodels the tumor microenvironment by driving osteoclastogenesis and compromising T cell effector function. Clinically, FST inversely correlates with PSA levels and associates with poor outcomes in enzalutamide-treated patients. We developed FST-Trap, which effectively neutralizes FST, resensitizes resistant tumors to AR-targeted therapy, and enhances immunotherapy efficacy. This establishes FST as both a biomarker and therapeutic target for AR-independent prostate cancer.
- 24 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Open AccessFollistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in advanced prostate cancer. Here we identify follistatin (FST), TGFβ superfamily antagonist, as a key driver of AR-independence and treatment resistance. During anti-AR therapy, cancer cells progressively lose the positive feedback loop between AR and BMP signaling, leading to FST upregulation that further suppresses this circuit. FST antagonizes BMP11-dependent AR maintenance and upregulates the lineage plasticity regulator SOX9, conferring resistance to enzalutamide while promoting stem-like properties and metastatic capabilities. FST also remodels the tumor microenvironment by driving osteoclastogenesis and compromising T cell effector function. Clinically, FST inversely correlates with PSA levels and associates with poor outcomes in enzalutamide-treated patients. We developed FST-Trap, which effectively neutralizes FST, resensitizes resistant tumors to AR-targeted therapy, and enhances immunotherapy efficacy. This establishes FST as both a biomarker and therapeutic target for AR-independent prostate cancer.
- 1 November 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 577, 165-172
PPBP as a marker of diabetic nephropathy podocyte injury via Bioinformatics Analysis
- 1 November 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 577, 165-172
PPBP as a marker of diabetic nephropathy podocyte injury via Bioinformatics Analysis
- 1 April 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (2) , 136-141
A comparison of dioctahedral smectite and iodine glycerin cream with topical mouth rinse in treatment of chemotherapy induced oral mucositis: A pilot study
- 1 April 2015
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 19 (2) , 136-141
A comparison of dioctahedral smectite and iodine glycerin cream with topical mouth rinse in treatment of chemotherapy induced oral mucositis: A pilot study